title: Ber-H2 (CD30) immunohistochemical staining of human fetal tissues.
abstract: OBJECTIVE
  CD30 antigen has long been considered to be restricted to the tumour cells of Hodgkin's disease and of anaplastic large cell lymphoma as well as to T and B activated lymphocytes. It is now apparent that the range of normal and neoplastic cells, which may express CD30 antigen, is much wider than was at first thought. In order to gain insight into the physiological function of CD30 antigen, we studied the distribution of its expression in the tissues of fetuses from week 8th to week 16th.
  
  
  METHODS
  We investigated the immunohistochemical expression of CD30 antigen in paraffin-embedded tissue samples representing all systems from 30 fetuses after therapeutic abortion at 8th to 10th and 12th to 16th week of gestation, respectively, using the monoclonal antibody Ber-H2.
  
  
  RESULTS
  Our results demonstrated that CD30 is expressed early in human fetal development (8th to 10th week of gestation) in several fetal tissues derived from all three germ layers (gastrointestinal tract, special glands of the postpharyngeal foregut, urinary, musculoskeletal, reproductive, nervous, endocrine systems), with the exception of the skin and hematolymphoid system (thymus), in which the antigen is expressed later on (10th week onwards). Expression of CD30 was restricted to the hematolymphoid system in the 12-16 weeks of gestation. No expression of the marker was observed in the respiratory and cardiovascular systems during the entire period examined.
  
  
  CONCLUSIONS
  CD30 antigen is of importance in cell development, and proliferation. It is also pathway-related to terminal differentiation in many fetal tissues and organs.
authors.affiliation: Department of Cytology, General Hospital of Chania, Crete, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Tamiolakis
authors.forename: N
authors.initials: N
authors.lastname: Papadopoulos
authors.forename: M
authors.initials: M
authors.lastname: Lambropoulou
authors.forename: J
authors.initials: J
authors.lastname: Venizelos
authors.forename: D
authors.initials: D
authors.lastname: Verettas
authors.forename: P
authors.initials: P
authors.lastname: Tsikouras
authors.forename: G
authors.initials: G
authors.lastname: Koutsougeras
authors.forename: H
authors.initials: H
authors.lastname: Papadopoulos
authors.forename: A
authors.initials: A
authors.lastname: Karpouzis
authors.forename: C
authors.initials: C
authors.lastname: Kouskoukis
mesh_terms: D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002454:Cell Differentiation; D004622:Embryo, Mammalian / Q000166:cytology* / Q000276:immunology; D005260:Female; D005865:Gestational Age; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D017730:Ki-1 Antigen / Q000032:analysis*; D008297:Male; D009363:Neoplasm Proteins / Q000032:analysis; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D013736:Testicular Neoplasms / Q000196:embryology
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D017730:Ki-1 Antigen; D009363:Neoplasm Proteins